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ABSTRACT
Introduction Acute-phase serum amyloid A (A-SAA)
has cytokine-like properties and is expressed at sites of
inflammation. We examined whether A-SAA-induced
pro-inflammatory mechanisms are mediated through
Toll-like receptor 2 (TLR2) in rheumatoid arthritis (RA).
Methods The effect of A-SAA on human embryonic
kidney (HEK), TLR2 or TLR4 cells was quantified by
nuclear factor (NF)-κB luciferase reporter assays. A-SAA-
induced RASFC and dHMVEC function were performed
in the presence of a specific neutralising anti-TLR2 mAb
(OPN301) (1 μg/mL) and matched IgG isotype control
Ab (1 μg/mL). Cell surface expression of intracellular
adhesion molecule (ICAM)-1, chemokine expression, cell
migration, invasion and angiogenesis were assessed by
flow cytometry, ELISA, Matrigel invasion chambers and
tube formation assays. MyD88 expression was assessed
by real-time PCR and western blot.
Results A-SAA induced TLR2 activation through
induction of NF-κB (p<0.05), but failed to induce
NF-κB in HEK-TLR4 cells, confirming specificity for TLR2.
A-SAA-induced proliferation, invasion and migration
were significantly inhibited in the presence of anti-TLR2
(all p<0.05), with no significant effect observed for
tumour necrosis factor-α-induced events. Additionally,
A-SAA-induced ICAM-1, interleukin-8, monocyte
chemoattractant protein-1, RANTES and GRO-α
expression were significantly reduced in the presence of
anti-TLR2 (all p<0.05), as was A-SAA induced
angiogenesis (p<0.05). Finally, A-SAA induced MyD88
signalling in RASFC and dHMVEC (p<0.05).
Conclusions A-SAA is an endogenous ligand for TLR2,
inducing pro-inflammatory effects in RA. Blocking the A-
SAA/TLR2 interaction may be a potential therapeutic
intervention in RA.
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune
disease characterised by synovial proliferation, neo-
vascularisation and leucocyte extravasation.1 2
Activation of the synovium transforms the lining
layer into a hyperplastic tumour-like ‘pannus’ that
is capable of destroying adjacent articular cartilage
and bone.3–5 Acute-phase serum amyloid A
(A-SAA) is an acute-phase protein that belongs to a
closely related group of 12–14 kDa apoproteins.6 7
During the inflammatory response, A-SAA is dra-
matically elevated in serum where it displaces
ApoA-1 and saturates high-density lipoprotein
(HDL),8 resulting in high levels of free circulating
A-SAA.9 Unlike other acute-phase proteins that are
synthesised primarily in the liver as part of the sys-
temic acute-phase response, A-SAA expression is
markedly increased at local sites of tissue inflamma-
tion.10 Such extra-hepatic A-SAA expression has
been demonstrated in brain amyloid plaques of
patients with Alzheimer’s disease and in athero-
sclerotic lesions.11 12 A-SAA is also the precursor of
AA, an insoluble degradation product, deposited in
a number of major organs in the progressive fatal
disease secondary amyloidosis.13
We and others have previously reported signifi-
cantly increased expression of A-SAA and its recep-
tors in RA synovial tissue and cells compared with
OA and healthy controls.14–17 Furthermore, A-SAA
is spontaneously released from RA synovial tissue
explants, with A-SAA levels at site of inflammation
significantly higher than systemic circulation,14 and
A-SAA induces chemokines, adhesion molecules,
angiogenesis, cytoskeletal rearrangement and
matrix metalloproteinases (MMPs) in RA synovial
cells in vitro.17–22 Furthermore, A-SAA has a high
affinity for the extracellular matrix components
and promotes RASFC fibroblasts invasion through
a β1-integrin and RhoGTPase-dependent mechan-
ism.22 23 A-SAA has two well-characterised recep-
tors, lipoxin A4 receptor/N-formyl peptide
receptor-like-1 (FPRL-1) and Scavenger receptor
class B member 1 (SR-B1) (formerly CD36 and
LIMPII analogous-1 (CLA-1)) both highly
expressed in RA ST compared with OA or healthy
control.16 19 24 Through FPRL-1 and SR-B1,
A-SAA activates many pro-inflammatory processes,
including cell migration/invasion, chemokine induc-
tion and MMP production.16 25–28 Blockade of
FRPL-1 and SR-B1 in an ex vivo RA synovial
explant culture model inhibits spontaneous chemo-
kine secretion, suggesting endogenous A-SAA is
active.14
Recent evidence has implicated Toll-like receptor
2 (TLR2) as an alternative receptor for A-SAA,29
TLR2 is expressed in the perivascular regions of
the joint,30 at the sites of attachment and invasion
into cartilage and bone, and on synovial macro-
phages.31 Increased expression of TLR2 has been
demonstrated in collagen-induced arthritis.32
Additionally, overexpression of dominant negative
forms of TLR2/4 adapter molecules MyD88 and
Mal/TIRAP or anti-TLR2 blockade inhibits spon-
taneous release of pro-inflammatory cytokines from
RA synovial cells and explants.33 34
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In this study, we examine whether TLR2 mediates
A-SAA-induced pro-inflammatory mechanisms in RA. The rapid
induction of A-SAA during inflammation, its localised expres-
sion at inflammatory sites and its ability to induce many
pro-inflammatory processes through TLR2 suggest that A-SAA is
directly involved in the pathogenesis of inflammatory joint
disease.
MATERIALS AND METHODS
Arthroscopy, isolation of RA synovial fibroblasts and
reagents
See online supplementary file 1.
Luciferase reporter gene assay
HEK293-TLR2 and HEK293-TLR4 cells were grown in
Dulbecco’s modified Eagle medium with GlutaMAX
(Gibco-BRL) supplemented with 10% fetal calf serum (FCS),
penicillin-streptomycin, noromycin and 200 μg/mL of G418 and
maintained at 37°C in a humidified atmosphere of 5% CO2.
36
HEK293-TLR2 and HEK293-TLR4 cells (2×104 cells/well;
96-well plate) were transfected with 80 ng/well luciferase
reporter gene plasmid for nuclear factor (NF)-κB,37 using
Lipofectamine 2000 as described by the manufacturer
(Invitrogen). In all cases, 40 ng/well of phRL-TK reporter gene
was co-transfected to normalise data for transfection efficiency.
After 24 h, cells were stimulated with A-SAA (0.01–10 μg/mL),
Pam2CSK4 (1 μg/mL), Pam3CSK4 (1 μg/mL) or lipopolysacchar-
ide (LPS) (0.01–10 μg/mL) for 24 h. Cell lysates were prepared
and reporter gene activity was measured using the Dual
Luciferase Assay system (Promega) as previously described.38
Data are expressed as the mean fold induction±SEM relative to
control levels from a minimum of three separate experiments.
Human microvascular endothelial cell culture and cell
growth assays
See online supplementary file 1.
dHMVEC tubule formation in vitro
Matrigel (50 μL) (Becton Dickinson, Mountain View, California,
USA) was plated in 48-well culture plates after thawing on ice
and allowed to polymerise for 1 h at 37°C in humidified air
with 5% CO2. dHMVEC were removed from culture, trypsi-
nised and resuspended at a concentration of 4×104 cells/mL in
EGM. In total, 500 μL of cell suspension was added to each
chamber in the presence of A-SAA (10 μg/mL), tumour necrosis
factor (TNF)-α (10 ng/mL)±OPN301 (1 μg/mL), or
IgG-matched control (1 μg/mL). The chambers were then incu-
bated for 24 h at 37°C in humidified air with 5% CO2.
Endothelial cell tubule formation was assessed using phase-
contrast microscopy and quantified as previously described.18
Analysis of cell surface ICAM-1 expression
RASFC or dHMVEC were plated to a density of 5×104 in
12-well plates (Falcon, Franklin Lakes, New Jersey, USA) for 48
h in medium plus supplements. Cells were stimulated with
A-SAA (10 μg/mL)±OPN301 (1 μg/mL) for 6 h, then incubated
with 0.3 μg/mL of phycoerythrin-conjugated mouse monoclonal
anti-intracellular adhesion molecule (ICAM)-1 or isotype-
matched IgG control (Becton Dickinson) for 30 min at 4°C.
Cells were then washed twice and fixed in 1% paraformalde-
hyde, and analysed by flow cytometry (FACS) using a FACScan
flow cytometer and Lysis II software (both from Becton
Dickinson).
Cytokine measurement in RASFC and dHMVEC
To assess the effect of TLR2 blockade on chemokine expression,
RASFC and dHMVEC were serum starved for 24 h, followed
by stimulation with A-SAA (10 μg/mL) in the presence or
absence of OPN301 (1 μg/mL) for a further 24 h. Supernatants
were harvested and protein levels of interleukin (IL)-8, mono-
cyte chemoattractant protein (MCP)-1, IL-6, RANTES and
GRO-α were measured by ELISA (R&D Systems) according to
the manufacturer’s protocol.
Wound repair assay
RASFC and dHMVEC were plated in 48-well plates, grown to
confluency, growth arrested for 24 h in serum-free Roswell Park
Memorial Institute medium or 1% EGM and scraped with a
sterile pipette tip to create a linear wound across the well. Cells
were subsequently stimulated for 24 h with A-SAA (10 μg/mL)
and TNF-α (10 ng/mL) in the presence or absence of OPN301
(1 μg/mL) or isotype-matched IgG (1 μg/mL) control antibody.
Migration was determined by visual assessment of cells that had
repopulated wound margins using phase-contrast microscopy.
Transwell invasion assay
Biocoat Matrigel Invasion Chambers (Becton Dickinson, UK)
were used to assess cell invasion in response to A-SAA
±OPN301. dHMVEC were seeded at a density of 2.5×104 per
well on 8 mm membranes pre-coated with Matrigel. EGM con-
taining A-SAA (10 mg/mL) or TNF-α (10 ng/mL) in the presence
or absence of OPN301 (1 μg/mL) or IgG-matched control anti-
body was added to the lower wells. Cells were allowed to
migrate for 24 h in EGM media containing 1% FCS. Migrating
cells attached to the lower membrane were fixed with 1% glu-
taraldehyde and stained with 0.1% crystal violet. To assess the
average number of migrating cells, cells were counted in five
random high-power fields.
RNA extraction from RASFC and dHMVEC
RASFC and dHMVEC were stimulated with A-SAA (10 mg/mL)
or TNF-α (10 ng/mL) in serum-free medium for 3–24 h prior to
RNA extraction using an RNeasy Mini Kit according to the
manufacturer’s protocol (Qiagen, Crawley, UK). The integrity of
RNA samples was assessed using a bioanalyzer (Agilent
Technologies, Cork, Ireland). Samples with a 260:280 nm ratio
of ≥1.8 and an RNA Integrity Number between 7 and 10 were
used in subsequent experiments. Isolated RNA was stored at
−80°C until further use.
RT-PCR
Total RNA (1 mg) was added to a 25 mL reaction volume con-
taining 200 U Superscript II in reverse transcriptase buffer
100 mM dithiothreitol (supplied with RT-enzyme), 40 units
RNasin Ribonuclease Inhibitor (Promega, Dublin, Ireland),
1.25 mM each of dATP, dCTP, dGTP and dTTP (Promega),
RNase-free water and 500 ng of oligo dTs (Promega). Reverse
transcription was performed at 42°C for 50 min. The reaction
was terminated by incubation at 95°C for 15 min. PCR primers
and probes for MyD88, GAPDH and β-actin (endogenous con-
trols) were designed by Applied Biosystems (Assays-on-Demand,
Applied Biosystems). Amplification reactions contained 1 mL
cDNA, 12.5 mL of Universal Taqman 2X PCR Mastermix
(Applied Biosystems, Cheshire, UK), 1.25 mL of primer and
probe mix and were brought to a total volume of 25 mL by the
addition of RNase-free water. All reactions/negative controls
were performed in triplicate using 96-well plates on the Roche
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LC480 (Roche Diagnostics, West Sussex, UK). Relative changes
in gene expression were determined using the Ct method.
Western blot for MyD88
RASFC and dHMVEC were incubated with A-SAA (10 μg/mL)
or TNF-α (10 ng/mL) for 15 min prior to lysis. Cell lysates were
separated by SDS-PAGE and transferred onto nitrocellulose
membranes. Western blotting was performed using an
anti-MyD88 rabbit polyclonal AbMyD88 (Abcam, Cambridge,
UK) according to the manufacturer’s protocol. Blots were devel-
oped using ECL (Pierce, Rockford, Illinois, USA) for detection
of horseradish peroxidase (HRP).
Statistical analysis
Statistical analysis was performed using SPSS 11 for Windows
(SPSS, Chicago, Illinois, USA). For comparisons between treated
and untreated RASFC, non-parametric Wilcoxon signed-rank
test for paired samples was performed. Parametric Student’s t
tests were used for analysis of dHMVEC and HEK293 cell data.
A p value of <0.05 was considered significant.
RESULTS
TLR2 is a functional receptor for A-SAA
The ability of A-SAA to drive TLR2-mediated NF-κB induction
was investigated using NF-κB luciferase reporter gene assays.
A-SAA induced TLR2-mediated NF-κB luciferase reporter gene
activity in a dose-dependent manner with maximum activity
observed at 10 and 50 mg/mL (see online supplementary figure
S1A). A-SAA induced a 15.7-fold increase (10 mg/mL) or
14.6-fold increase (50 mg/mL) in TLR2-mediated NF-κB lucifer-
ase reporter gene activity compared with control (p<0.05)
(figure 1A). Additionally, TLR2-mediated NF-κB luciferase
reporter gene activity was significantly enhanced following
stimulation with the TLR2 agonists, Pam2CSK4 and Pam3CSK4
(p<0.05). LPS-induced TLR4 mediated NF-κB reporter gene
activity in a dose-dependent manner (see online supplementary
figure S1B), with no effect observed for A-SAA (figure 1B).
SAA-induced cell growth and angiogenesis is mediated via
TLR2
RASFC proliferation significantly increased by 314% following
stimulation with A-SAA (10 mg/mL) (p=0.02) and by 399% in
response to TNF-α stimulation (p=0.005) (see online supple-
mentary figure S2A). A-SAA-induced cell growth was inhibited
by 37.4% in the presence of OPN301, with no significant effect
observed on TNF-α-induced cell growth (see online supplemen-
tary figure S2A). Similar effects were observed in dHMVEC
where anti-TLR2 significantly reduced A-SAA cell growth
(p=0.002) (figure 2B), but had no effect on TNF-α (see online
supplementary figure S2A).
A significant increase in the formation of tube-like structures
was demonstrated in the presence of A-SAA alone (p<0.05)
(figure 2C, D), an effect that was inhibited in the presence of
OPN301 (p<0.05). Figure 2C shows representative images of
increased tube formation following A-SAA stimulation, as
demonstrated by an increase in the number of connecting
branches between two endothelial cells. This effect was inhib-
ited to near basal in the presence of anti-TLR2.
TLR2 mediates A-SAA-induced chemokine expression in
RASFC and dHMVEC
A-SAA significantly increased IL-6, IL-8, MCP-1, GRO-α and
RANTES expression in both RASFC (figure 3A) and dHMVEC
(figure 3B) (p<0.05). Co-incubation of cells with SAA and
OPN301 resulted in significant reductions in SAA-induced cyto-
kine activity (p<0.05). In contrast, OPN301 had no effect on
TNF-α-induced cytokine production in either RASFC or
dHMVEC (data not shown).
TLR2 mediates A-SAA-induced adhesion, invasion and
migration
Figure 4A shows representative histograms demonstrating increased
RASFC surface expression of ICAM-1 in response to A-SAA com-
pared with basal control, an effect that was inhibited by OPN301
(figure 4A, i). A-SAA significantly increased RASFC ICAM-1
expression from a mean fluorescent intensity (MFI) of 24.71±5.44
to 88.27±18.68 (p<0.05), which was significantly reduced to
36.34±10.96 in the presence of OPN301 (figure 4A, ii) (p<0.05).
Similarly, A-SAA significantly increased cell surface ICAM-1 expres-
sion on dHMVEC, from an MFI of 209.83±109.34 to 724.58
±74.5 (p<0.05), an effect that was significantly inhibited by
OPN301 to 255.49 (p<0.01) (data not shown).
dHMVEC invasion was significantly induced by A-SAA com-
pared with control (figure 4B), an effect similar to stimulation
with TNF-α. Blockade of TLR2 significantly decreased
A-SAA-induced invasion (p<0.05) (figure 4B, C), but had no
effect on TNF-α-induced invasion (see online supplementary
figure S2B). Figure 4D shows representative images of wound
repair where repopulation of wound margins was observed in
response to A-SAA, an effect that was inhibited in the presence
of OPN301.
A-SAA induces MyD88 expression
As all known effector functions of TLR2 signalling depend on
the MyD88 adaptor protein, we next examined whether MyD88
could be induced by A-SAA. As shown in figure 5, A-SAA
Figure 1 Acute-phase serum amyloid A (A-SAA) is a functional ligand
for Toll-like receptor 2 (TLR2). The effect of A-SAA on nuclear factor
(NF)-κb luciferase reporter activity in (A) HEK293-TLR2 cells and (B)
HEK293-TLR4 cells. Results are shown as the mean±SEM (n=3).
*p<0.01, #p<0.05 compared with basal control. LPS,
lipopolysaccharide.
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Figure 2 Acute-phase serum amyloid
A (A-SAA)-induced cell growth and
angiogenesis is Toll-like receptor 2
(TLR2) dependent. (A) Rheumatoid
arthritis (RA) synovial fibroblasts
(RASFC) and (B) microvascular
endothelial cells (dHMVEC) were
stimulated with SAA (10 μg/mL) in the
presence or absence of OPN301 (1 μg/
mL) or IgG control (1 mg/mL) for 72 h
and cell growth was assessed by
crystal violet assay. (C) Representative
photomicrographs of dHMVEC tubule
formation on Matrigel matrix following
24 h of incubation with SAA (10 μg/
mL)±OPN301 (1 μg/mL). Quantitative
analysis of the number of connecting
branches at baseline and in response
to A-SAA±OPN301 (1 mg/mL) or IgG
(1 mg/mL) control shown in (D). The
tube analysis was determined from five
sequential fields (magnification ×40)
focusing on the surface of the
Matrigel. Results are shown as the
mean±SEM (n=5−7). *p<0.05
significantly different.
Figure 3 Toll-like receptor 2 (TLR2) mediates acute-phase serum amyloid A (A-SAA)-induced chemokine expression. (A) Rheumatoid arthritis synovial
fibroblasts (RASFC) or (B) microvascular endothelial cells (dHMVEC) were stimulated with SAA (10 μg/mL) in the presence or absence of OPN301 (1 μg/
mL) or IgG control (1 μg/mL) for 24 h. Supernatants were harvested and quantified for interleukin (IL)-6, IL-8, monocyte chemoattractant protein
(MCP)-1, RANTES and GRO-α by ELISA. Results are shown as the mean±SEM (n=4) *p<0.05, **p<0.01 significantly different.
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increased transcript levels of MyD88 in both RASFC (figure 5A)
and dHMVEC (figure 5B), reaching maximal levels at 24 and 6
h, respectively. Additionally, A-SAA increased expression of
MyD88 protein in both cell types, as demonstrated by western
blot (figure 5A, B, ii). In contrast, TNF-α had no effect on
MyD88 expression (see online supplementary figure S3).
DISCUSSION
In this study, we demonstrate that A-SAA is capable of driving
NF-κB through TLR2, but not TLR4. At a functional level,
A-SAA-induced proliferation, invasion and migration were sig-
nificantly inhibited in the presence of OPN301 (anti-TLR2)
with no effect on TNF-α-induced mechanisms. Additionally,
Figure 4 Toll-like receptor 2 (TLR2) mediates acute-phase serum amyloid A (A-SAA)-induced adhesion, invasion and migration. (A) RASFC were
stimulated with A-SAA (10 μg/mL)±OPN301 (1 μg/mL) or IgG control (1 μg/mL) and expression of ICAM-1 was detected by flow cytometric analysis.
(A)(i) Representative histogram showing intercellular adhesion molecule 1 (ICAM-1) on RA synovial fibroblasts (RASFC) following stimulation with
SAA (10 μg/mL)±OPN301 (1 μg/mL) for 24 h. (A)(ii) Quantification of ICAM-1 expression in RASFC, data represented as mean fluorescent intensity
(n=5). (B) Representative photomicrograph showing microvascular endothelial cell (dHMVEC) invasion. Cells were stimulated with SAA (10 μg/mL) in
the presence or absence of OPN301 (1 μg/mL) or IgG control (1 mg/mL) for 24 h. Invading cells attached to the lower membrane were fixed (1%
glutaraldehyde) and stained (1% crystal violet) (original magnification ×40). (C) Bar graph quantifying dHMVEC invasion (n=4). (D) Representative
images showing RASFC repopulating the wound in response to A-SAA (10 μg/mL), an effect that was blocked in the presence of OPN301 (1 μg/mL),
with no effect observed for IgG control (1 μg/mL) (n=3). Results are shown as the mean±SEM. *p<0.05 significantly different.
Figure 5 Acute-phase serum amyloid
A (A-SAA) induces MyD88. MyD88
mRNA expression was quantified in
RASFC and HMVEC following
stimulation with A-SAA (10 mg/mL) by
real-time PCR. Results are shown as
the mean±SEM from n=4 (HMVEC) or
n=5 (RASFC) experiments (A, B) (i)
Western blot analysis for MyD88 in
RASFC A (ii) and dHMVEC B (ii)
following A-SAA (10 mg/mL)
stimulation for 24 h (n=3). *p<0.05,
**p≤0.01 significantly different.
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A-SAA-induced angiogenesis, ICAM-1, IL-6, IL-8, MCP-1,
RANTES and GRO-α expression in RASFC and dHMVEC were
significantly reduced in the presence of OPN301. Finally, we
show that A-SAA induces MyD88 signalling in RASFC and
dHMVEC. Thus, A-SAA-induced pro-inflammatory mechanisms
in RA are mediated, in-part, via the TLR2 receptor.
A-SAA, a major acute-phase protein, is highly elevated both in
circulation and locally in tissues during various pathological
conditions.12 39 40 In addition, elevated A-SAA levels correlate
with an increased risk of adverse cardiovascular endpoints
including myocardial infarction41 and is strongly expressed in
unstable atherosclerotic plaques.12 Additionally, A-SAA plays a
central role in lipid metabolism and in acute inflammation,
associates with HDL, displacing Apo-AI, resulting in increased
HDL saturates, where it renders HDL pro-atherogenic.
Furthermore, serum A-SAA levels correlate closely with RA
disease activity and can differentiate RA from other arthropa-
thies in a cohort of patients with early arthritis.42 Together, this
suggests that A-SAA is actively involved in innate immunity and
inflammation and suggests a common role for A-SAA as an
inflammatory mediator, and an important protein in lipid
metabolism and transport.
In this study, we demonstrate that A-SAA-induced
pro-inflammatory effects are in part mediated through TLR2
activation with no effect observed for TLR4. Furthermore, we
demonstrate in RASFC that A-SAA-induced proliferation, adhe-
sion and migration is mediated by TLR2. Previous in vitro
studies have demonstrated the cytokine-like properties of
A-SAA, which induces the release of several cytokines in
RASFC, dHMVEC, human monocytes and neutrophils.14 43 44
Furthermore, A-SAA promotes leucocyte recruitment and
matrix degradation, key processes in the pathogenesis of
RA.18 19 45 Additional receptors for A-SAA, FPRL-1 and SR-B1
have been demonstrated in the RA joint and mediate
A-SAA-induced pro-inflammatory mechanisms.15 16
TLRs have been implicated in the pathogenesis of RA with
studies demonstrating increased expression of TLR2 in the RA
joint, and TLR2 activation in RA synovial explants, RASFC and
macrophages. Functional significance of TLR2 has been demon-
strated in collagen-induced arthritis models and in
TLR2-deficient mice. Several potential TLR2 ligands have been
implicated, including heat shock protein/GP96, fibronectin frag-
ments, hyalauronidase oligosaccharides and HMBG-1, all of
which are highly expressed in RA synovial fluid.14 46–48 The
existence of a ligand is further supported by studies showing that
conditioned media from RA synovial explants can activate macro-
phages in a MyD88 and Mal-dependent manner.30 Given that
TLR2 is a major pattern recognition receptor, that SAA is spon-
taneously released from RA tissue and that its functional effects
are in part mediated by TLR2, this suggests that SAA may act as
an endogenous ligand for TLR2 in the RA joint and contributes
to inflammation through persistent activation of this receptor.
We and others have demonstrated A-SAA can directly induce
angiogenic processes, adhesion molecules and chemokines
expression in vitro and in vivo,14 effects that are mediated
through FRPL-1 and SR-B1.16 17 24 However, this is the first
study to show a role for TLR2 in mediating A-SAA-induced
angiogenic mechanisms. Specifically, we showed that OPN301
significantly inhibited A-SAA-induced tube formation, invasion
and chemokine expression. This is supported by studies
showing TLR2 activation promotes angiogenesis, cell adhesion
and invasion in RA, effects that are in part mediated through
the key angiogenic signalling pathway Ang2/Tie2.49 In addition,
TLR2 is expressed in SM perivascular regions,50 and in vitro
TLR2 activation induces VEGF/IL-8 expression in synovial
fibroblasts and chondrocytes,51 52 and MMP-9 in corneal epi-
thelial cells and THP-1 macrophages.53 Furthermore, we have
demonstrated using whole-tissue RA synovial explant cultures
that OPN301 significantly inhibits spontaneous release of
pro-inflammatory cytokines IL-1β, TNF-α, IFN-γ and IL-8, 34
and MMP-3, MMP-2 and MMP-9.54 In addition, culture of
RASFC with conditioned media from OPN301-treated RA
explants inhibited RASFC migration and invasion compared
with IgG control.54 Therefore, the ability of TLR2 to mediate
A-SAA-induced changes in vascularity, chemokine expression
and adhesion further support the hypothesis that A-SAA
engages TLR2 to act locally in the RA joint.
Finally, we demonstrated in RASFC and dHMVEC that SAA
significantly induced MyD88, an adaptor protein for TLR2.
Signalling from MyD88 to the activation NF-κB and activator
protein-1 regulates inflammatory responses and a number of
studies have demonstrated induced MyD88/MAL pathway in RA
synovial fibroblasts, macrophages and tissue.30–34 50 Previous
reports have shown that mice deficient for the MyD88 adaptor
molecule for IL-1R/TLR signalling failed to develop joint inflam-
mation after induction of streptococcal cell wall arthritis, con-
firming an essential role for MyD88 in arthritis.53 Furthermore,
RA synovial explant conditioned media can activate macrophages
in a MyD88-dependent manner.30 As Myd88-mediated signal-
ling pathways mainly stimulate the activation of NF-κB, our
results suggest that MyD88 and NF-κB mediate the
pro-inflammatory and angiogenic functions of A-SAA in RA.
A-SAA has traditionally been viewed as an acute-phase react-
ant and potential biomarker in inflammation, similar to erythro-
cyte sedimentation rate or C reactive protein. In this study, we
have described critical pro-inflammatory functions in human
cells to suggest that A-SAA is a functionally relevant
pro-inflammatory molecule that exerts its effects via TLR2 sig-
nalling. The responses to human endothelium and RA cells
provide a strong, possibly critical link, between A-SAA and the
pathogenesis of vascular and joint inflammation. In addition,
these data further support a role for A-SAA in other diseases
where high A-SAA expression at site of inflammation has been
demonstrated including atherosclerosis, Alzheimer’s disease,
type II diabetes and metabolic syndrome.8–13 55 56 A better
understanding of A-SAA/TLR2-mediated inflammatory pathways
may lead to novel treatment strategies for inflammatory
diseases.
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